Payers and patient compliance will determine winners as Incivek and Victrelis hit HCV
This article was originally published in Scrip
Executive Summary
While data on Vertex/Janssen's Incivek (telaprevir) published on 27 June in the New England Journal of Medicine provided little new insight into the drug's efficacy beyond what was already known from the EASL meeting in April, the companies believe that they have the edge over Merck's boceprevir in winning round physicians to using their drug in both naive and previously-treated patient groups. However, as pointed out in a recent survey, the pattern of prescribing for the two HCV NS3/4A protease inhibitors is likely to be heavily influenced by the behaviours of payer organisations, many of which seem unwilling to reimburse either drug in treatment-naive patients.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.